2017－2020年流感流行季节河北省甲型H1N1流感病毒耐药性及耐药基因分析

姜彩肖; 韩光跃; 李岩; 刘艳芳; 刘兰芬; 齐顺祥

doi:10.3784/jbjc.202103240155

2017－2020年流感流行季节河北省甲型H1N1流感病毒耐药性及耐药基因分析

Drug resistance of influenza A (H1N1) pdm09 virus in Hebei, 2017–2020

摘要

摘要:
目的分析河北省2017 — 2020年流感流行季节甲型H1N1流感病毒对神经氨酸酶抑制剂类药物（NAI）的耐药情况，为流感的预防控制提供依据。
方法选取2017 — 2020年流感流行季节37株甲型H1N1流感病毒毒株进行生物学耐药实验，使用荧光发光法检测病毒对奥司他韦和扎那米韦的药物敏感性。选取38株甲型H1N1流感病毒提取核酸后对神经氨酸酶NA基因进行PCR扩增，测序后对耐药位点进行分析。
结果选取的“A/河北新华/SWL1106/2017”对奥司他韦敏感性降低（IC₅₀=30.98 nmol/L），其余36株甲型H1N1流感病毒全部对奥司他韦和扎那米韦敏感，对奥司他韦的半数抑制浓度（IC₅₀）平均数为0.46 （0.07～1.14 ）nmol/L；对扎那米韦的IC₅₀平均数为0.27 （0.07～0.85 ）nmol/L。序列分析发现1株发生了H275Y突变，为奥司他韦耐药株。
结论 2017—2020年河北省流行的绝大部分甲型H1N1流感病毒对NAI类药物敏感。

Abstract:
Objective To analyze the resistance of influenza A (H1N1) pdm09 virus to neuraminidase inhibitors (NAIs) in Hebei province during 2017–2020 and provide evidence for the prevention and control of influenza．
Methods A total of 37 strains of influenza A (H1N1) pdm09 virus isolated in Hebei during 2017–2020 were selected for oseltamivir and zanamivi resistance tests with fluorescence radiation assay. A total of 38 strains of influenza A (H1N1) pdm09 virus were selected for neuraminidase (NA) sequencing analysis.
Results The median of half maximal inhibitory concentration (IC₅₀) of oseltamivir to strain A/Hebeixinhua/SWL1106/2017 was 30.98 nmol/L. To 36 virus strains, the average IC₅₀ of oseltamivir was of 0.46 nmol/L (ranged 0.07–1.14 nmol/L) while the average IC₅₀ of zanamivi was 0.27 nmol/L (ranged 0.07–0.85 nmol/L). Sequence analysis showed that 1 strain had H275Y mutation in amino acid of the NA gene, suggesting that the strain was oseltamivir resistant.
Conclusion The majority of influenza A (H1N1) pdm09 virus strains isolated in Hebei during 2017–2020 were sensitive to NAIs.

HTML全文

参考文献(20)

施引文献

资源附件(1)